Portfolio Reallocation Strategy
SkyView Investment Advisors Reallocates Portfolio Toward SPACs While Trimming Major Holdings
Anonymous
Key Points
1
The new Drugs Made In America Acquisition II holding represented approximately 2.1% of SkyView Investment Advisors’ portfolio and ranked as its 12th-largest position.
2
SkyView owned about 0.14% of Cohen Circle Acquisition Corp. II and 0.69% of Cantor Equity Partners after establishing the new positions.
3
All three newly purchased securities carried unfavorable or cautious rating signals in the reports: Cohen Circle and Drugs Made In America were each rated “Sell” by the cited consensus data, while Cantor Equity Partners was upgraded by Wall Street Zen from “Sell” to “Hold.”
4
Despite SkyView’s sharp reduction in Canadian Pacific Kansas City, the company remained broadly institutionally held, with institutional investors and hedge funds owning 72.20% of its stock; analysts cited in the report included Citigroup, which maintained a “Buy” rating while raising its price target to $109.
5
Canadian Pacific Kansas City’s institutional ownership contrasts with Mastercard’s even higher institutional concentration: 97.28% of Mastercard shares were reportedly held by institutional investors and hedge funds.
SkyView Investment Advisors shifted its portfolio in the second quarter, buying into three new positions while cutting major stakes in established companies. The firm acquired 250,000 shares of Drugs Made In America Acquisition II Corp., valued at about $2.5 million and representing its 12th-largest holding, alongside smaller positions in Cohen Circle Acquisition Corp. II and Cantor Equity Partners. Watchlist News reported that SkyView simultaneously slashed its Canadian Pacific Kansas City holding by 93.3% to just 3,000 shares worth $260,000 and reduced Mastercard by 86.4% to 300 shares worth $154,000.
New SPAC Bets Despite Wall Street Skepticism
SkyView's three new investments all carry red flags from analyst consensus ratings. According to Ticker Report, both Cohen Circle Acquisition Corp. II and Drugs Made In America Acquisition II received "Sell" ratings, while Cantor Equity Partners was rated "Hold" after a recent upgrade from "Sell." The moves suggest SkyView is betting against the grain, placing $4.55 million combined into special-purpose acquisition companies that mainstream analysts view unfavorably.
Massive Exits From Transportation and Payments Giants
SkyView trimmed long-standing positions in two blue-chip stocks. Watchlist News noted the fund slashed Canadian Pacific Kansas City by over 93%, leaving just a $260,000 stake. Despite the exit, institutional investors still owned 72.20% of CPKC, with Citigroup maintaining a "Buy" rating and a $109 price target. The Mastercard cut was even more dramatic: the firm reduced its position by 86.4%, leaving only 300 shares worth $154,000.
Mastercard shows far heavier institutional concentration than CPKC. Ticker Report reported that 97.28% of Mastercard shares are held by institutional investors and hedge funds, suggesting limited room for fund movements to move the stock price significantly.
Pattern of Rapid Sector Rotation and Trimming
SkyView's Q2 activity extended beyond the five companies highlighted. Watchlist News reported the firm sold 110,074 shares of Interactive Brokers Group, cutting that stake by 87.3%. Ticker Report also documented a reduction in Griffon Corporation holdings by 84.5%, leaving just 3,000 shares. These moves reveal a fund actively rotating out of established positions across finance, industrial, and payments sectors.
Meanwhile, SkyView established new stakes in growth-stage companies. Watchlist News reported a 30,000-share purchase of Flywire Corporation, while Ticker Report documented a $1.97 million position in Archimedes Tech SPAC Partners II, which became its 16th-largest holding. The pattern shows SkyView moving capital from mature blue-chips into younger, higher-risk opportunities.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
10
Reach
29
A
AnonymousAuthor
